National Hospital for Neurology and Neurosurgery

Briefing on Capitol Hill Urges More Government Action and Investment in the Epilepsies

Retrieved on: 
Wednesday, May 24, 2023

WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.

Key Points: 
  • WASHINGTON, May 24, 2023 /PRNewswire/ -- In cooperation with the Congressional Epilepsy Caucus, organizations including the Epilepsy Foundation, Epilepsies Action Network, CURE Epilepsy, Rare Epilepsy Network and DEE-P Connections hosted a briefing on Capitol Hill on May 17 to educate about the epilepsies and call for more government action and investment in the epilepsies.
  • (R-NC-3) and Jim Costa (D-CA-21) spoke about their personal connections to epilepsy and the importance of the caucus.
  • "My son developed epilepsy when he was 14 and it took us months to get the right treatment for him," said Congressman Murphy.
  • The annual total healthcare burden for people living with the epilepsies and/or seizures is at least $54 billion.

FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

Retrieved on: 
Monday, January 9, 2023

“We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said Mr. Zeeshan Saeed, President of FSD Pharma.

Key Points: 
  • “We are excited about the incorporation of FSD Pharma Australia, where we have an excellent opportunity to advance our pipeline,” said Mr. Zeeshan Saeed, President of FSD Pharma.
  • “Australia is a hotbed for clinical stage biotech companies, and our drug development programs will be able to take advantage of facilities offered by various government incentives in Australia,” added Mr. Saeed.
  • Chataway, Dhanda and Lê have agreed to join our international panel to contribute to our current and new programs,” said Dr. Lakshmi Kotra, CEO of Lucid Psycheceuticals, a wholly owned subsidiary of FSD Pharma.
  • Dr. Chataway received his Bachelor of Medicine & Surgery from Oxford University, and Doctor of Philosophy from Cambridge University.

Vigil Neuroscience to Host ALSP KOL Event on December 6, 2022

Retrieved on: 
Monday, November 28, 2022

The event will provide further details on the ALSP disease background, epidemiology and patient journey.

Key Points: 
  • The event will provide further details on the ALSP disease background, epidemiology and patient journey.
  • To access a live webcast of this event, please visit Events & Presentations in the Investors section of the Vigil website at www.vigilneuro.com .
  • Vigil Neuroscience routinely posts information that may be important to investors in the Investors section of its website at https://www.vigilneuro.com .
  • The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease

Retrieved on: 
Tuesday, June 7, 2022

BRISBANE, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced promising, final data from its open-label Phase 2 clinical trial of ANX005 in patients with Huntington’s disease (HD).

Key Points: 
  • Annexons unique approach to tackle HD targets C1q, the initiating molecule of the classical complement pathway, to slow or halt classical complement diseases.
  • ANX005 is designed to fully block C1q and the entire classical complement pathway with the aim of preserving functioning synapses to slow or halt neurodegeneration.
  • The apparent continued stabilization of clinical function over nine months is notable, and generally not expected in a progressive disease like HD.
  • The study enrolled a total of 28 patients, of whom 23 completed both six-months of treatment and subsequent three-month follow-up period.

Reneo Pharmaceuticals Hosting Key Opinion Leader Webinar on McArdle Disease and other Genetic Mitochondrial Myopathies

Retrieved on: 
Tuesday, September 28, 2021

IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader (KOL) webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4, 2021, at 12 pm Eastern Time.

Key Points: 
  • IRVINE, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that management will host a key opinion leader (KOL) webinar on McArdle Disease and other genetic mitochondrial myopathies on Monday, October 4, 2021, at 12 pm Eastern Time.
  • Dr. Quinlivan will discuss the current treatment landscape, patient journey, and unmet medical need for patients with McArdle disease and other genetic mitochondrial myopathies.
  • Reneos Chief Medical Officer, Dr. Alex Dorenbaum, will also discuss the Companys clinical program for its lead candidate, REN001, in the treatment of McArdle Disease.
  • She has been principal investigator for a number of clinical trials in DMD, centronuclear myopathy, and McArdle disease.

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
Wednesday, September 15, 2021

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston

Abingworth strengthens investment team with new appointments in the US and UK

Retrieved on: 
Wednesday, September 15, 2021

LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.

Key Points: 
  • LONDON, Sept. 15, 2021 /PRNewswire/ --Abingworth, a leading international life sciences investment group, announces three new appointments to its investment team in the UK and US.
  • Jay will be based at the firm's Menlo Park, CA office and Lucille and Diya will be based in London, UK.
  • ABV 8 Abingworth Bioventures 8; ACCD2 Abingworth Clinical Co-Development Fund 2
    Abingworth is a leading transatlantic life sciences investment firm.
  • Abingworth supports its portfolio companies with a team of experienced professionals at offices in London, Menlo Park (California), and Boston